PhRMA Statement About Accessing Online Health Information
Washington, D.C. (November 9, 2009) —
Pharmaceutical Research and Manufacturers of America (PhRMA) Senior
Vice President Ken Johnson issued the following statement regarding
the FDA’s Nov. 12-13 hearing (view
testimony | view
slide show) on patients’ access to reliable health
information online:
“PhRMA
member companies are committed to providing patients and
healthcare professionals with balanced, accurate and useful
information about the life-saving and life-enhancing medicines they
research, develop and manufacture. To that end, PhRMA looks forward
to working with the Food and Drug Administration (FDA) and diverse
stakeholders to identify ways in which our member companies may
continue to communicate about their medicines online in truthful,
scientifically accurate and non-misleading ways.
“Given the unprecedented growth of the Internet as a source
of health information, the FDA should facilitate the appropriate
use of online media by America’s pharmaceutical research and
biotechnology companies to provide FDA-regulated information on
medicines.
“Federal entities, such as the White House, the Centers for Disease Control
and Prevention, and the FDA itself already take advantage of new
media technologies, such as blogs and Twitter™, to
communicate important health information directly to patients and
their doctors.
“Going forward, the Agency could promote the responsible use
of the Internet to benefit patients by shining a brighter spotlight
on legitimate, FDA-regulated health communication. One way the FDA
could accomplish that aim would be to adopt a single, easily
recognizable logo to help guide patients and healthcare providers
to FDA-regulated information about medical products, including
manufacturer Web sites.
“Leveraging the FDA’s logo – or a universal
FDA-approved graphic symbol – in search results and
throughout the Web would inform patients, at a glance, that they
are visiting a legitimate site that contains comprehensive
FDA-regulated benefit and risk information. Such a graphic symbol
could be combined with a universal warning statement to provide an
indication of risk when there is little space (e.g., a
search result or tweet).
“Already, biopharmaceutical companies provide the only
FDA-regulated promotional information about medicines online.
“The Agency’s leadership in regulating responsible use
of social media would come at a time when the Internet has become
an invaluable resource for patients and healthcare providers
seeking health information, as evidenced by a recent Pew Research
Center survey. Sixty-one percent of American adults now look online
for health information, and 42 percent of adults say they or
someone they know has been helped by health information found on
the Internet, according to Pew.
- “The FDA could help patients and could better serve the public health by following this week’s public dialogue with guidance that outlines clear standards to help patients access truthful, reliable information on the Internet. Chief among PhRMA’s suggestions:“The FDA should adopt a prominent universal safety symbol – the FDA logo or other FDA-approved symbol – to indicate that a linked page contains the manufacturer’s FDA-regulated risk information. Use of this symbol throughout the Web would help healthcare professionals and patients identify the official Web sites of FDA-approved medical products containing reliable and comprehensive information about benefits and risks.
- “Because millions of Internet users are already accustomed to viewing pop-ups, mouse roll-over text, hyperlinks and other new media communication tools, the FDA should follow the lead of the Federal Trade Commission (FTC) in recognizing the space limitations of certain formats and the flexibility of the Internet in communicating warnings.
- “Just as FDA and the White House have embraced certain Internet technologies that emphasize brevity, such as blog entries and Twitter™, the Agency should facilitate the use of such technologies by biopharmaceutical manufacturers. For example, FDA should facilitate communication of abbreviated benefit and risk information, provided there is easy access to longer, comprehensive warnings through a prominently labeled hyperlink. The Agency could, for instance, facilitate the ability of manufacturers to combine brief ‘introductions’ to a health topic with prominent and clearly marked links that would provide access to the prescription medicine’s full indication and comprehensive risk information. Similarly, such information could be provided using roll-over or pop-up technology.
- “PhRMA applauds the vigilance of the FDA and FTC in uncovering and disrupting Internet-based sales of fraudulent H1N1 flu treatments as the nation faces a serious H1N1 outbreak and prepares for the annual flu season. Due to the very real public health threat and lack of accountability posed by illegal Internet drug sales, the FDA should redouble such enforcement efforts.
“PhRMA hopes that our proposals help to advance the
conversation about how to best communicate the benefits and risks
of medical products in new, online media.”
The Pharmaceutical Research and Manufacturers of America (PhRMA)
represents the country’s leading pharmaceutical research and
biotechnology companies, which are devoted to inventing medicines
that allow patients to live longer, healthier, and more productive
lives. PhRMA companies are leading the way in the search for new
cures. PhRMA members alone invested an estimated $50.3 billion in
2008 in discovering and developing new medicines. Industry-wide
research and investment reached a record $65.2 billion in
2008.
PhRMA Internet Address: www.phrma.org
For information on stories of hope and survival, visit: http://sharingmiracles.com/
PhRMA en Español: www.nuestraphrma.org
For information on how innovative medicines save lives, visit:
www.innovation.org
For information on the Partnership for Prescription Assistance,
visit: www.pparx.org
For more information on public health emergencies, visit:
www.rxresponse.org
For information on the danger of imported drugs, visit: www.buysafedrugs.info
Pharma Industry News Archive
2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec
